➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Mallinckrodt
Merck
AstraZeneca
Express Scripts

Last Updated: December 2, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Bardoxolone

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Bardoxolone?

Bardoxolone is an investigational drug.

There have been 28 clinical trials for Bardoxolone. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2016.

The most common disease conditions in clinical trials are Kidney Diseases, Renal Insufficiency, Chronic, and Diabetes Mellitus. The leading clinical trial sponsors are Reata Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd., and NYU Langone Health.

There are nineteen US patents protecting this investigational drug and seventy-four international patents.

Recent Clinical Trials for Bardoxolone
TitleSponsorPhase
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)Reata Pharmaceuticals, Inc.Phase 2/Phase 3
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)NYU Langone HealthPhase 2/Phase 3
Phase I Study of RTA 402 in Obese AdultsKyowa Kirin Co., Ltd.Phase 1

See all Bardoxolone clinical trials

Clinical Trial Summary for Bardoxolone

Top disease conditions for Bardoxolone
Top clinical trial sponsors for Bardoxolone

See all Bardoxolone clinical trials

US Patents for Bardoxolone

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Bardoxolone   Start Trial Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole Trustees of Dartmouth College (Hanover, NH)   Start Trial
Bardoxolone   Start Trial Compositions and methods for restoring the stratum corneum and treating dermatological diseases New York University (New York, NY) BIOKEYS FOR FLAVORS, LLC (Norwood, NJ)   Start Trial
Bardoxolone   Start Trial Inhibitors and methods of use thereof The Trustees of Dartmounth College (Hanover, NH)   Start Trial
Bardoxolone   Start Trial CDDO-compounds and combination therapies thereof The Trustees of Dartmouth College (Hanover, NH) Board of Regents, The University of Texas System (Austin, TX)   Start Trial
Bardoxolone   Start Trial Synthesis and biological activities of new tricyclic-bis-enones (TBEs) Trustees of Dartmouth University (Hanover, NH)   Start Trial
Bardoxolone   Start Trial CDDO-compounds and combination therapies thereof Board of Regents, The University of Texas System (Austin, TX) The Trustees of Dartmouth College (Hanover, NH)   Start Trial
Bardoxolone   Start Trial Synthesis and biological activities of new tricyclic-bis-enones (TBEs) Trustees of Dartmouth College (Hanover, NH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Bardoxolone

Drugname Country Document Number Estimated Expiration Related US Patent
Bardoxolone World Intellectual Property Organization (WIPO) WO2016033132 2034-08-26   Start Trial
Bardoxolone World Intellectual Property Organization (WIPO) WO2012170467 2031-06-07   Start Trial
Bardoxolone Australia AU2003303128 2022-05-13   Start Trial
Bardoxolone Canada CA2485565 2022-05-13   Start Trial
Bardoxolone European Patent Office EP1507541 2022-05-13   Start Trial
Bardoxolone Japan JP2006515859 2022-05-13   Start Trial
Bardoxolone World Intellectual Property Organization (WIPO) WO2004064723 2022-05-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Mallinckrodt
Merck
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.